A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma

This trial is testing a combination of targeted therapy, immunotherapy, and a specially engineered virus (oncolytic herpes virus) given before surgery in patients with locally advanced head and neck cancer — to try to shrink the tumor and improve surgical outcomes. **You may be eligible if...** - You are 18–70 years old - You have been newly diagnosed with locally advanced squamous cell carcinoma of the head and neck (not including nasopharynx, salivary glands, or thyroid) - Your cancer has not spread to distant organs - For oropharyngeal cancer, your tumor must be HPV-negative, or if HPV-positive, must be stage III–IVB **You may NOT be eligible if...** - Your cancer has spread to distant organs - You have previously received treatment for head and neck cancer - You have significant heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.